The Annals Take our Readership Survey!
home help contact us subscription past issues search current issue
QUICK SEARCH:   [advanced]


     


Published Online, 10 January 2006, www.theannals.com, DOI 10.1345/aph.1G501.
 The Annals of Pharmacotherapy: Vol. 40, No. 2, pp. 295-298. DOI 10.1345/aph.1G501
© 2006 Harvey Whitney Books Company.
This Article
Right arrow Résumé Freely available
Right arrow Extracto Freely available
Right arrow Full Text
Right arrow PDF
Right arrow For Our Patients
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Articles Ahead of Print
Right arrow [Order Reprint]
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Cahoon, W. D
Right arrow Articles by Kockler, D. R
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Cahoon, W. D, Jr
Right arrow Articles by Kockler, D. R

DRUG INFORMATION ROUNDS

Mycophenolate Mofetil Treatment of Myasthenia Gravis

William D Cahoon Jr, PharmD

Pharmacy Practice Resident, Virginia Commonwealth University Health System, Medical College of Virginia Hospitals, Richmond, VA

Denise R Kockler, PharmD

Director, Drug Information Services, Virginia Commonwealth University Health System, Medical College of Virginia Hospitals

Reprints: Dr. Cahoon, Virginia Commonwealth University Health System, Medical College of Virginia Hospitals, 401 N. 12th St., PO Box 980042, Richmond, VA 23298-0042, fax 804/225-3920, wcahoon{at}mcvh-vcu.edu

OBJECTIVE: To review published literature evaluating the effectiveness of mycophenolate mofetil for the treatment of myasthenia gravis (MG).

DATA SOURCES: Searches of MEDLINE (1966–August 2005) and Cochrane Database (1993–August 2005) were conducted. Studies conducted in humans and published in English were retrieved. Additional data were identified through subsequent bibliographic reviews.

DATA SYNTHESIS: Interruption of T- and B-lymphocyte proliferation in various autoimmune diseases has been investigated. Mycophenolate is known to inhibit lymphocyte proliferation and has shown improved clinical responses in several autoimmune diseases including lupus erythematosus, rheumatoid arthritis, and systemic vasculitis. Data suggesting similar benefits in MG treatment have been reported in case reports, retrospective analyses, an open-label trial, and a randomized, double-blind trial.

CONCLUSIONS: Limited evidence from retrospective analyses and clinical trials suggests that mycophenolate is a possible treatment option for patients with MG. Improvement in clinical symptoms and a steroid-sparing effect have been reported when mycophenolate is used in this patient population. Larger, randomized, controlled, and comparative trials are needed to establish optimal dose, time to effect, specific therapeutic role, and long-term safety for mycophenolate when used for treating MG.

Key Words: myasthenia gravis, mycophenolate

Published Online, January 10, 2006. www.theannals.com, DOI 10.1345/aph.1G501


This article has been cited by other articles:


Home page
 LupusHome page
A Sinclair and R Baildon
Mycophenolate mofetil: an overview
Lupus, November 1, 2006; 15(11_suppl): 70 - 77.
[PDF]


homecopy help contact us subscription past issues search current issue
Copyright © 2006 by Harvey Whitney Books Company.